An interventional study of Cognitive rehabilitation program in Stem Cell Transplantation, Pediatric Cancer and Acute Lymphoblastic Leukemia, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 6 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Stanford University · Not applicable, Interventional, and Supportive care
This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 17 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.
Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Cognitive rehabilitation program
Behavioral: Cognitive rehabilitation program
Number of participants who complete the post-transplant neurocognitive intervention program
Number of participants who enroll in and are able to complete the neurocognitive intervention program, measured at 3 months after enrollment.
Time frame: 3 months after enrollment
Number of participants who complete at least half of the neurocognitive intervention program
Number of participants who complete at least 50% of scheduled sessions in the neurocognitive intervention program.
Time frame: 3 months after enrollment
Change in WISC-IV or WAIS-IV scores
Change in intellectual functioning scores (Full Scale IQ, Verbal Comprehension, Perceptual Reasoning, Working Memory, and Processing Speed indices) from pre-treatment to 1 and 2 years post-treatment.
Time frame: Baseline, 1 year post-treatment, 2 years post-treatment
Change in WRAML-2 scores
Change in verbal and visual memory scores from pre-treatment to 1 and 2 years post-treatment using the Wide Range Assessment of Memory and Learning, Second Edition (WRAML-2).
Time frame: Baseline, 1 year post-treatment, 2 years post-treatment
Change in executive functioning scores (D-KEFS or NEPSY-II)
Change in executive functioning scores from pre-treatment to 1 and 2 years post-treatment, using Delis Kaplan Executive Function System (D-KEFS; ages 8-21) or NEPSY-II subtests (ages 6-7).
Time frame: Baseline, 1 year post-treatment, 2 years post-treatment
Change in CPT-II scores
Change in sustained attention/vigilance scores from pre-treatment to 1 and 2 years post-treatment using Conners' Continuous Performance Test, Second Edition (CPT-II).
Time frame: Baseline, 1 year post-treatment, 2 years post-treatment
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stanford University